Actively Recruiting
Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo
Led by Western Galilee Hospital-Nahariya · Updated on 2025-07-20
182
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.
CONDITIONS
Official Title
Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singleton pregnancy at term
- Meconium-stained amniotic fluid
You will not qualify if you...
- Intrauterine fetal death
- Group B Streptococcus (GBS) carriers
- Allergy to zinacef
- Antibiotic treatment for other indications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Galilee Medical center
Nahariya, Israel
Actively Recruiting
Research Team
M
Maya Frank Wolf, prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here